

Bartłomiej Kalaska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4774188/publications.pdf>

Version: 2024-02-01

28
papers

444
citations

759233

12
h-index

713466

21
g-index

28
all docs

28
docs citations

28
times ranked

711
citing authors

#	ARTICLE	IF	CITATIONS
1	The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats. <i>Vaccine</i> , 2022, 40, 1996-2002.	3.8	1
2	Monitoring of Anticoagulant Activity of Dabigatran and Rivaroxaban in the Presence of Heparins. <i>Journal of Clinical Medicine</i> , 2022, 11, 2236.	2.4	1
3	Cardiovascular and Respiratory Toxicity of Protamine Sulfate in Zebrafish and Rodent Models. <i>Pharmaceutics</i> , 2021, 13, 359.	4.5	4
4	Preclinical Toxicity and Safety of MM-129â€”First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer. <i>Pharmaceutics</i> , 2021, 13, 1222.	4.5	6
5	Reversal Activity and Toxicity of Heparin-Binding Copolymer after Subcutaneous Administration of Enoxaparin in Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11149.	4.1	1
6	Monitoring of Cardiorespiratory Parameters in Ratsâ€”Validation Based on Pharmacological Stimulation. <i>Pharmaceutics</i> , 2021, 14, 1223.	3.8	0
7	Kynurenine Pathway in Chronic Kidney Disease: Whatâ€™s Old, Whatâ€™s New, and Whatâ€™s Next?. <i>International Journal of Tryptophan Research</i> , 2020, 13, 117864692095488.	2.3	31
8	Modulation of the Paracrine Kynurenic System in Bone as a New Regulator of Osteoblastogenesis and Bone Mineral Status in an Animal Model of Chronic Kidney Disease Treated with LP533401. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5979.	4.1	6
9	P0870THE ACTIVATION OF KYNURENIC SYSTEM IN BONE TISSUE AS A NEW REGULATOR OF OSTEOBLASTOGENESIS IN RATS WITH EXPERIMENTAL CHRONIC KIDNEY DISEASE DURING LP533401 THERAPY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
10	Neurobehavioral effects of uremic toxinâ€”indoxyl sulfate in the rat model. <i>Scientific Reports</i> , 2020, 10, 9483.	3.3	38
11	Heparin-Binding Copolymer as a Complete Antidote for Low-Molecular-Weight Heparins in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 373, 51-61.	2.5	10
12	The Inhibitory Effect of Protamine on Platelets is Attenuated by Heparin without Inducing Thrombocytopenia in Rodents. <i>Marine Drugs</i> , 2019, 17, 539.	4.6	6
13	The neutralization of heparan sulfate by heparin-binding copolymer as a potential therapeutic target. <i>RSC Advances</i> , 2019, 9, 3020-3029.	3.6	9
14	FP443THE INFLUENCE OF TRYPTOPHAN HYDROXYLASE INHIBITOR LP533401 ON KYNURENINE CONCENTRATION IN BONE TISSUE IN THE EXPERIMENTAL MODEL OF CHRONIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
15	Oxidized glycerophosphatidylcholines in diabetes through non-targeted metabolomics: Their annotation and biological meaning. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1120, 62-70.	2.3	16
16	LP533401 restores bone health in 5/6 nephrectomized rats by a decrease of gut-derived serotonin and regulation of serum phosphate through the inhibition of phosphate co-transporters expression in the kidneys. <i>Bone</i> , 2018, 113, 124-136.	2.9	10
17	Anticoagulant Properties of Poly(sodium 2-(acrylamido)-2-methylpropanesulfonate)-Based Di- and Triblock Polymers. <i>Biomacromolecules</i> , 2018, 19, 3104-3118.	5.4	16
18	Pharmacogenetic considerations of anticoagulant medication. <i>Journal of Physiology and Pharmacology</i> , 2018, 69, .	1.1	4

#	ARTICLE	IF	CITATIONS
19	Elevated Levels of Peripheral Kynurenine Decrease Bone Strength in Rats with Chronic Kidney Disease. <i>Frontiers in Physiology</i> , 2017, 8, 836.	2.8	34
20	A link between central kynurenine metabolism and bone strength in rats with chronic kidney disease. <i>PeerJ</i> , 2017, 5, e3199.	2.0	7
21	The Toxicokinetic Profile of Dex40-GTMAC3â€™a Novel Polysaccharide Candidate for Reversal of Unfractionated Heparin. <i>Frontiers in Pharmacology</i> , 2016, 7, 60.	3.5	17
22	Serum metabolic fingerprinting after exposure of rats to quinolinic acid. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 131, 175-182.	2.8	4
23	Heparin-binding copolymer reverses effects of unfractionated heparin, enoxaparin, and fondaparinux in rats and mice. <i>Translational Research</i> , 2016, 177, 98-112.e10.	5.0	20
24	The toxicology of heparin reversal with protamine: past, present and future. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 897-909.	3.3	95
25	Nonclinical Evaluation of Novel Cationically Modified Polysaccharide Antidotes for Unfractionated Heparin. <i>PLoS ONE</i> , 2015, 10, e0119486.	2.5	28
26	New arginine substituted derivative of poly(allylamine hydrochloride) for heparin reversal. <i>MedChemComm</i> , 2014, 5, 489.	3.4	14
27	Antithrombotic Effects of Pyridinium Compounds Formed from Trigonelline upon Coffee Roasting. <i>Journal of Agricultural and Food Chemistry</i> , 2014, 62, 2853-2860.	5.2	31
28	Cationic derivative of dextran reverses anticoagulant activity of unfractionated heparin in animal models of arterial and venous thrombosis. <i>European Journal of Pharmacology</i> , 2012, 686, 81-89.	3.5	35